MedTrace Logo

Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression

NCT00320632 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2015-08-19

No results posted yet for this study

Summary

This study will determine the effectiveness of desipramine in improving cellular signaling, and thereby decreasing symptoms of depression in people with major depressive disorder (MDD).

Conditions

Interventions

DRUG

Desipramine

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Harvard Medical School (HMS and HSDM)

    lead OTHER

Principal Investigators

  • Joseph J. Schildkraut, MD · Department of Psychiatry, Harvard Medical School

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1990-08-31
Completion
1993-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00320632 on ClinicalTrials.gov